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Background: Patients (pts) with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) represent a challenging pt population to 
control with few treatment options and inadequate exposure in clinical trials. We investigated the 2-year safety and efficacy of saxagliptin versus 
placebo (pbo) in 16,492 pts with T2DM in the SAVOR-TIMI 53 trial according to baseline renal function (fxn).
methods: Pts were stratified as normal/mild [eGFR >50 mL/m; N=13,916], moderate [eGFR 30-50 mL/m; N=2,240], or severe renal dysfxn [eGFR 
<30 mL/m]; N= 336]. The primary endpoint (PEP) was CV death, MI, or ischemic stroke.
results: The effect of saxagliptin versus pbo on PEP was similar regardless of renal fxn (Figure). The relative risk of hospitalization for heart failure 
(HHF), a component of the 2nd endpoint, with saxagliptin was also similar by renal fxn (normal/mild HR=1.24; moderate HR=1.46; severe HR=0.94; 
P-interaction=0.43), though the absolute risk difference with saxagliptin was higher with moderate renal dysfxn. Pts with renal dysfxn achieved a 
lower HbA1c with saxagliptin (7.4% vs 7.6%; P<0.0001). Other efficacy and adverse events (AE) were balanced (all P-int≥0.12).
conclusion: SAVOR studied over 2500 pts with CKD and T2DM and provides insight into the efficacy and safety of saxagliptin. Regardless of 
baseline renal fxn, saxagliptin enhanced glycemic control, neither increased nor decreased the risk of ischemic CV events, increased the risk of HHF 
and otherwise had an overall balanced AE profile.
 
